NYSE:CNMDMedical Equipment
CONMED (CNMD) Valuation Review as It Exits Gastroenterology and Refocuses on Core Growth Areas
CONMED (CNMD) is reshaping its portfolio after deciding to exit gastroenterology, accelerating the end of its GORE VIABIL biliary stent distribution deal as Olympus takes over U.S. rights in early 2026.
See our latest analysis for CONMED.
Despite this strategic refocus, CONMED’s 1 year total shareholder return of negative 44.21 percent and year to date share price return of negative 41.8 percent suggest sentiment is still cautious, with momentum clearly fading rather than building.
If this...